Auranofin

• 产品号: A6733
• 分子式: C20H34AuO9PS
• 分子量: 678.483871
• 纯 度: ≥98% (HPLC)

产品别名

• 标题: Auranofin
• IUPAC标准名: [(2R,3R,4S,5R,6S)-3,4,5-tris(acetyloxy)-6-{[(triethyl-λ^5-phosphanylidene)aurio]sulfanyl}oxan-2-yl]methyl acetate
• IUPAC传统名: triethylphosphine gold
• 别名: 3,4,5-Triacetyloxy-6-(acetyloxymethyl) oxane-2-thiolate triethylphosphanium; 1-Thio-β-D-glucopyranosatotriethylphosphine gold-2,3,4,6-tetraacetate; SKF 39162

产品登记号

• MDL号: MFCD00080759
• EC号: 251-801-9

产品性质

• Empirical Formula (Hill Notation): C20H34AuO9PS
• 纯度: ≥98% (HPLC)
• 外观: powder
• 溶解度: DMSO: ≥5 mg/mL
• GHS警示词: Danger
• GHS危险声明: H301-H361
• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• 个人保护装置: dust mask type N95 (US), Eyeshields, Faceshields, Gloves
• GHS警示性声明: P281-P301 + P310
• RID/ADR: UN 2811 6.1/PG 3
• 危险公开号: 63-22
• RTECS编号: MD6500000
• 安全公开号: 36/37
• 保存温度: room temp
• 联合国危险货物等级: 6.1
• 联合国危险货物编号: 2811
• 联合国危险货物包装类别(PG): 3
• 德国WGK号: 3

产品详细信息

详细说明 (简体中文)

Application
Auranofin inhibits both leukocyte activation pathways at multiple sites and the release of inflammatory mediators from human macrophages, basophils, and pulmonary mast cells. Auranofin also inhibits 5-lipoxygenase in human neutrophils, IKB kinase (IKK) by modifying Cys-179 of the IKKβ subunit 5 and selenoenzyme thioredoxin reductase (TrxR) which is involved in the defense against oxidative stress. Auranofin is a disease-modifying antirheumatic drug (DMARD) and has been used to study the anti-proliferative effects against OVCAR-3 human ovarian carcinoma cells.
Biochem/physiol Actions
Auranofin inhibits various leukocyte activation pathways at multiple sites. Auranofin inhibits the release of inflammatory mediators from human macrophages, basophils, and pulmonary mast cells. The compound also inhibits 5-lipoxygenase in human neutrophils. Auranofin is a disease-modifying antirheumatic drug (DMARD). The compound is a potent inhibitor of selenoenzyme thioredoxin reductase (TrxR), which is involved in defense against oxidative stress. Auranofin is an efficient inducer of mitochondrial membrane permeability transition pore in the presence of calcium ions related to its inhibition of mitochondrial thioredoxin reductase. Auranofin inhibits IKB kinase (IKK) by modifying Cys-179 of the IKKβ subunit 5.

详细说明 (English)

Application
Auranofin inhibits both leukocyte activation pathways at multiple sites and the release of inflammatory mediators from human macrophages, basophils, and pulmonary mast cells. Auranofin also inhibits 5-lipoxygenase in human neutrophils, IKB kinase (IKK) by modifying Cys-179 of the IKKβ subunit 5 and selenoenzyme thioredoxin reductase (TrxR) which is involved in the defense against oxidative stress. Auranofin is a disease-modifying antirheumatic drug (DMARD) and has been used to study the anti-proliferative effects against OVCAR-3 human ovarian carcinoma cells.
Biochem/physiol Actions
Auranofin inhibits various leukocyte activation pathways at multiple sites. Auranofin inhibits the release of inflammatory mediators from human macrophages, basophils, and pulmonary mast cells. The compound also inhibits 5-lipoxygenase in human neutrophils. Auranofin is a disease-modifying antirheumatic drug (DMARD). The compound is a potent inhibitor of selenoenzyme thioredoxin reductase (TrxR), which is involved in defense against oxidative stress. Auranofin is an efficient inducer of mitochondrial membrane permeability transition pore in the presence of calcium ions related to its inhibition of mitochondrial thioredoxin reductase. Auranofin inhibits IKB kinase (IKK) by modifying Cys-179 of the IKKβ subunit 5.